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OBJECTIVES We sought to prospectively compare nitrogen-13 (13N)-ammonia/18fluorodeoxyglucose (18FDG)
positron emission tomography (PET)–guided management with stress/rest technetium-99m
(99mTc)-sestamibi single-photon emission computed tomography (SPECT)– guided
management.
BACKGROUND Patients with evidence of jeopardized (i.e., ischemic or viable) myocardium may benefit from
revascularization, whereas patients without it should be treated with drugs. Both PET and
SPECT imaging have been proven to delineate jeopardized myocardium. When patient
management is based on identification of jeopardized myocardium, it is unknown which
technique is most accurate for long-term prognosis.
METHODS In a clinical setting, 103 patients considered for revascularization with left ventricular wall
motion abnormalities and suspicion of jeopardized myocardium underwent both PET and
SPECT imaging. The imaging results were used in a randomized fashion to determine
management (percutaneous transluminal coronary angioplasty [PTCA], coronary artery
bypass graft surgery [CABG] or drug treatment). Follow-up for cardiac events (cardiac death,
myocardial infarction and revascularization) was recorded for 28 6 1 months. The study was
designed to have a power of 80% to detect a 20% difference in the event rate between PET-
and SPECT-based management.
RESULTS Management decisions in 49 patients randomized to PET (12 who had PTCA, 14 CABG
and 23 drug therapy) were comparable with 54 patients randomized to SPECT (15 who had
PTCA, 13 CABG and 26 drug therapy). In terms of cardiac event-free survival, no
differences between PET and SPECT were observed (11 vs. 13 cardiac events for PET and
SPECT, respectively; p 5 NS by the Kaplan-Meier statistic).
CONCLUSIONS No difference in patient management or cardiac event-free survival was demonstrated
between management based on 13N-ammonia/18FDG PET and that based on stress/rest
99mTc-sestamibi SPECT imaging. Both techniques may be used for management of patients
considered for revascularization with suspicion of jeopardized myocardium. (J Am Coll
Cardiol 2001;37:81–8) © 2001 by the American College of Cardiology
Revascularization management in patients with coronary
artery disease is an important clinical issue, and assessment
of jeopardized (i.e., ischemic or viable) myocardium before
revascularization allows prediction of regional and global
left ventricular function improvement. Several nuclear myo-
cardial imaging techniques with different radiopharmaceu-
tical agents—thallium-201 (201Tl) (1–4), technetium-99m
(99mTc)-sestamibi (5–7) and 18fluorodeoxyglucose (18FDG)
See page 89
(3,8–21)—dobutamine stress echocardiography (3,22–25)
and magnetic resonance imaging (26,27) are used to detect
myocardium that could benefit from revascularization. For
all of these imaging modalities, varying sensitivities and
specificities for postrevascularization recovery of left ventric-
ular function have been reported in an analysis of pooled
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data (28). Among these techniques, 18FDG positron emis-
sion tomographic (PET) imaging is believed to be most
accurate by demonstrating high sensitivity and specificity
values.
However, from the clinical point of view, long-term
prognosis is also important. Several studies have indicated
that patients with evidence of jeopardized myocardium
benefit from revascularization for prognosis (12–15,29,30),
but that similar patients who are only treated with drugs
have a high risk for future cardiac events (13–15). Moreover,
patients without signs of jeopardized myocardium appear to
be at increased risk of perioperative complications and
should continue drug treatment (12). These data suggest
that jeopardized myocardium should be revascularized for
prognostic reasons. However, most studies addressing prog-
nosis in jeopardized myocardium are small and retrospective
and do not include a comparison with other viability
assessment techniques.
To date, it is unknown which technique is most accurate
for determination of patient management and for long-term
prognosis when management is based on identification of
jeopardized myocardium. In the current study, we examined
in a prospective, blinded, randomized fashion, the impact of
nitrogen-13 (13N)-ammonia/18FDG PET–guided man-
agement and stress/rest 99mTc-sestamibi single-photon
emission computed tomographic (SPECT) imaging–
guided management (percutaneous transluminal coronary
angioplasty [PTCA], coronary artery bypass graft surgery
[CABG] or drug treatment) on cardiac event-free survival.
All patients included in the study were potential candidates for
revascularization, and in all patients, assessment of jeopardized
(i.e., ischemic or viable) myocardium was indicated.
METHODS
Patient selection. The study group was recruited from
patients referred for routine diagnostic coronary angiogra-
phy for clinical reasons (e.g., angina, myocardial ischemia,
arrhythmias, heart failure) and in whom a revascularization
procedure was considered. In our institution, coronary
angiography results and clinical data are discussed on a daily
basis by the revascularization team of the Thorax Center.
This team consists of a thoracic surgeon, an invasive
cardiologist, the patients’ cardiologist and a nuclear cardi-
ologist, and they determine patient management (i.e.,
CABG, PTCA or drug treatment). Patients were eligible
for the present study if, as a result of the revascularization
team discussion, additional information was needed regard-
ing the amount or the absence of jeopardized myocardium
in an area exhibiting wall motion abnormalities supplied by
a coronary artery with significant (.50%) stenosis. In the
eligible patients, the amount of jeopardized myocardium
had to have an impact on patient management (PTCA,
CABG or drug treatment), and a revascularization proce-
dure had to be technically feasible by demonstrating ade-
quate target vessels. Furthermore, the patients’ clinical
condition had to permit protocol participation. Patients
,20 years old and .80 years old, patients with unstable
angina and patients with recent (,4 weeks) myocardial
infarction were excluded. If they met all of the aforemen-
tioned criteria, patients were candidates for scintigraphic
evaluation.
The study was approved by the Institutional Review
Board of the University Hospital Groningen, and 112
patients were included. When informed, written consent
was obtained, patients underwent an interview, physical
examination, routine laboratory investigation and echocar-
diography for assessment of left ventricular function. A
history of myocardial infarction was documented either by
clinical history or pathologic Q waves on the rest electro-
cardiogram (ECG). Baseline New York Heart Association
functional class was assessed on the basis of exercise toler-
ance for angina or heart failure symptoms. Then patients
were referred to the Department of Nuclear Medicine and
to the PET Center and underwent both stress/rest 99mTc-
sestamibi SPECT and 13N-ammonia/18FDG PET imaging.
SPECT. Stress/rest 99mTc-sestamibi SPECT myocardial
imaging was done using a two-day protocol. Stress imaging
was performed after patients had discontinued vasoactive
medication for five plasma half-lives and had refrained from
caffeinated beverages for a minimum of 12 h before the
studies. For stress imaging, infusion of dipyridamole
(0.56 mg/kg body weight in 4 min) was used, and 600 MBq
of 99mTc-sestamibi was injected 6 min after the start of
dipyridamole infusion. Imaging started after 60 min. Three
days later, rest imaging was performed 60 min after 600 MBq
of 99mTc-sestamibi was injected at rest. Imaging was per-
formed using a Siemens Orbiter single-head gamma camera
(Siemens Gammasonics Inc., Des Plaines, Illinois)
equipped with a low energy, high resolution collimator. A
15% window was set over the 140-KeV photon peak.
Sixty-four projection images were obtained in the supine
position in a 180° arc, imaging for 20 s/view. All images
were acquired on a computer in a 64 3 64 matrix (word
mode) and stored on an optical disk. The images were
reconstructed and corrected for uniformity and center of
rotation offset. No attenuation or scatter correction was
applied. The images were prefiltered with a two-
dimensional Butterworth filter, with an order equal to 6.
The cutoff frequency was 0.5. After ramp-filtered back-
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projection, slices of two pixels were generated. Slices were
reoriented according to the anatomic axis of the heart.
Reconstructed slices were displayed as short-axis slices and
horizontal and vertical long-axis slices. Analysis was done
using the ICON software (Siemens Medical Systems, Hoff-
man Estates, Illinois). Unprocessed planar images were
displayed in the cine format to exclude significant patient
motion or breast or diaphragmatic attenuation. Displayed
short-axis slices, as well as horizontal long-axis and vertical
long-axis slices, were then normalized to the maximal tracer
uptake in the heart and shown in color scale for semiquan-
titative analysis, and polar maps for rest and stress images
were reconstructed. The images were analyzed by two
experienced readers who reached a consensus reading. The
following classification was used: normal myocardium; jeop-
ardized myocardium (.10% reversibility or rest activity
$50% of maximal activity); and nonviable myocardium
(lowest activity in the defect #50% of maximal activity and
#10% reversibility) (7,31,32). According to these criteria,
the physicians of the Nuclear Medicine Department de-
picted regions exhibiting normal, nonviable and jeopardized
myocardium in a uniform, blinded polar map (Fig. 1), which
was sent to the Trial Coordination Center.
PET. Patients underwent dynamic 13N-ammonia dipyrid-
amole and 18FDG PET imaging using a one-day protocol,
as described previously (33). Briefly, PET studies were
performed after patients had discontinued vasoactive med-
ication for five plasma half-lives and had refrained from
caffeinated beverages for a minimum of 12 h before the
studies. Imaging was performed in the supine position with
a Siemens ECAT 951 positron camera (Siemens CTI,
Knoxville Tennessee), measuring 31 planes simultaneously
over 10.8 cm. Measured resolution of the system was 6 mm
at full width half maximum. Data were automatically
corrected for accidental coincidence and dead time. Patients
were positioned with the help of a rectilinear scan. Photon
attenuation was measured using a retractable external ring
source filled with germanium-68/gallium-68. Dipyridamole
perfusion imaging was performed infusing dipyridamole
(0.56 mg/kg in 4 min). Imaging was started by injecting
370 MBq of 13N-ammonia 6 min after the start of dipyri-
damole infusion and continued for 15 min (frames: 12 3
10 s, 1 3 2 min, 1 3 4 min, 1 3 7 min). To stimulate
18FDG uptake, patients were given 75 g of glucose orally
before the scanning procedure, and in diabetic patients,
18FDG imaging was done with the hyperinsulinemic eugly-
cemic glucose clamp technique (34). Imaging with 18FDG
was performed after injection of 185 MBq of 18FDG and
continued for 55 min (frames: 8 3 15 s, 4 3 30 s, 1 3
1 min, 1 3 5 min, 1 3 10 min, 1 3 15 min, 1 3 20 min).
Data processing and analysis to detect normal, jeopardized
myocardium (mismatch) and nonviable myocardium
(match) were performed as described previously (33). Then
physicians from the PET Center depicted regions exhibit-
ing normal, nonviable and jeopardized myocardium in a
uniform, blinded polar map (Fig. 1), which was sent to the
Trial Coordination Center.
Randomization. At the Trial Coordination Center, pa-
tients were randomized to receive either 13N-ammonia/
18FDG PET or 99mTc-sestamibi SPECT, for determina-
tion of patient management. Weighted randomization was
performed on the basis of gender, age and single-vessel or
multivessel disease.
Patient management. After randomization, only the uni-
formly blinded polar map depicting the results of the
technique which the patient had been randomized to receive
was given by the Trial Coordination Center to the revas-
cularization team of the Thorax Center. By using this
uniform polar map, the revascularization team was com-
pletely unaware of the information; they did not know
whether the polar map showed PET or SPECT results. The
results of the nonrandomized polar map were not shown to
the revascularization team. For the second time, the team
discussed the coronary angiography, ventriculography and
clinical data, but this time with the requested scintigraphic
results of the tests on jeopardized, nonviable and normal
myocardium. For revascularization, our regular criteria were
applied and included the presence of at least 20% jeopar-
dized myocardium in the region supplied by a coronary
artery with stenosis (.50%). This cutoff value has recently
been reported to accurately predict functional improvement
of left ventricular function (17). Depending on the results
depicted in the blinded polar map and according to the
revascularization criteria, the team decided to perform
revascularization (CABG or PTCA) or to continue drug
treatment. Bypass surgery or PTCA was then performed
according to the regular urgency-based schedule, and com-
plete revascularization was attempted in all revascularized
patients. After the revascularization procedure, daily ECGs
and cardiac enzyme studies were obtained to identify new
ST segment elevation or Q-waves associated with an in-
crease in cardiac enzymes, consistent with significant
periprocedural myocardial infarction.
Figure 1. Example of a uniform, blinded polar map consisting of a frame
in which areas of jeopardized and nonviable myocardium could be depicted
by using a computer. A separate polar map was created for PET results and
SPECT results by different physicians. After randomization, only the polar
map of the technique which the patient was randomized to receive was
presented to the clinicians, who subsequently determined treatment. By
using this uniform polar map design, the clinicians were completely
unaware whether the polar map showed PET or SPECT results. ANT 5
anterior; INF 5 inferior; LAT 5 lateral; SEP 5 septal.
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Follow-up. Six months later, patients visited the outpa-
tient clinic, where information on clinical events was ob-
tained. Information on survival status and clinical events was
again obtained by use of a detailed questionnaire to the
patient’s cardiologist or general practitioner, or by review of
hospital records at 28 6 1 months after randomization
(median 28 months, maximum 46 months).
End points. The end point in this study was cardiac
event-free survival during follow-up, starting at randomiza-
tion. Cardiac events included cardiac death, myocardial
infarction and unintended revascularization. Cardiac death
was defined as sudden death, death after the onset of
symptoms suggestive of cardiac ischemia and death due to
heart failure. Noncardiac death was defined as death due to
all other causes. Myocardial infarction was defined as an
increase in cardiac enzymes or new pathologic Q-waves on
the ECG, or both. Unintended revascularization was de-
fined as PTCA or CABG performed due to worsening of
the patient’s clinical condition, rather than the PTCA or
CABG assigned by the revascularization team when
patient management was determined.
Statistics. On the basis of previous data from a compara-
tive study using 18FDG PET and stress-redistribution 201Tl
imaging, performed by Tamaki et al. (16), we expected a
total event rate of 20%. Presuming a 20% higher cardiac
event rate for patients randomized to SPECT, we estimated
that our sample size had to include at least 95 patients to
obtain a power of 80%. To compensate for patient with-
drawal, we included 112 patients. Changes within groups
were assessed using the paired Student t test or the Wil-
coxon signed-rank test. Groups were compared by using the
Student t test or the Wilcoxon two-sample test, as appro-
priate. According to the intention-to-treat principle, cardiac
event-free survival was analyzed with the first cardiac event
per patient, using the Kaplan-Meier and log-rank statistic.
To determine the subgroups of patients that may benefit
from 13N-ammonia/18FDG PET or 99mTc-sestamibi
SPECT, multiple Cox regression analysis was performed on
the first occurrence of a cardiac event for all baseline
variables. For statistical analysis, SAS version 6.12 (Cary,
North Carolina) was used. All data are expressed as the
mean value 6 SEM. All p values were two-sided, and p ,
0.05 was considered significant.
RESULTS
Baseline characteristics. Of the 112 study patients, 103
were randomized and nine were not (one patient died, three
withdrew from the study, one had a failed PET scan and
four had progressive disease requiring treatment before
randomization). The patients’ baseline characteristics are
summarized in Table 1. The patients were characterized by
echocardiographic left ventricular ejection fraction .30% or
#30%. There were no differences in baseline characteristics
or medical history between the group randomized to 13N-
ammonia/18FDG PET and the group randomized to
99mTc-sestamibi SPECT.
Scintigraphic results. The prevalence of the mean amount
of normal, nonviable and jeopardized myocardium was not
different between the 103 PET and 103 SPECT images.
Positron emission tomography exhibited 68% normal, 16%
nonviable and 16% jeopardized myocardium, whereas
SPECT exhibited 64% normal, 20% nonviable and 16%
jeopardized myocardium.
Treatment. Intended treatment, as determined by the
revascularization team, was not different between the PET
and SPECT groups (PET: 12 patients had PTCA, 14 had
CABG and 23 had drug therapy; SPECT: 15 patients had
PTCA, 13 had CABG and 26 had drug therapy). Two
patients died before they received their intended treatment:
one patient randomized to PET experienced untreatable
ventricular fibrillation, and one patient randomized to
SPECT experienced sudden death. Before initiation of
treatment, no events occurred in other patients. Although
the treating clinicians decided that one patient randomized
to PET and five patients randomized to SPECT could not
receive the intended treatment, the received treatment
(PET: 11 patients had PTCA, 13 had CABG and 24 had
drug therapy; SPECT: 10 patients had PTCA, 13 had
CABG and 30 had drug therapy) did not significantly differ
from the intended treatment. In these patients, the intended
treatment was not effectuated, because in one patient
CABG was not performed due to worsening clinical con-
dition (not allowing a surgical intervention; the patient had
to be treated with drugs), in three patients PTCA was not
performed because the patients had been stabilized on drugs
while waiting for the intended revascularization procedure,
one patient refused to undergo PTCA and one patient
received CABG instead of PTCA because of technical
anatomic reasons. Notably, the treating physicians who
Table 1. Baseline Characteristics
PET Group
(n 5 49)
SPECT Group
(n 5 54)
Age (years) 62 6 2 63 6 1
Vessel disease (1:.1) 13 (27)/36 (73) 12 (22)/42 (78)
Gender (male/female) 40 (82)/9 (18) 49 (91)/5 (9)
NYHA functional class 2.5 6 0.08 2.3 6 0.11
Ejection fraction
(#30%/.30%)
17 (35)/32 (65) 19 (35)/35 (65)
Weight (kg) 80.4 6 1.6 81.9 6 1.5
Height (m) 1.74 6 0.01 1.76 6 0.01
Previous MI 44 (90) 49 (91)
Previous PTCA 12 (24) 11 (20)
Previous CABG 14 (29) 15 (28)
Diabetes mellitus 9 (18) 6 (11)
Hypercholesterolemia 17 (35) 21 (39)
Hypertension 17 (35) 13 (25)
Family history of CAD 21 (43) 28 (52)
Continue variables are expressed as the mean value 6 SEM; categoric variables are
expressed as the number (%) of the patients in the randomized group.
CABG 5 coronary artery bypass grafting; CAD 5 coronary artery disease; MI 5
myocardial infarction; NHYA 5 New York Heart Association; PET 5 positron
emission tomography; PTCA 5 percutaneous transluminal coronary angioplasty;
SPECT 5 single-photon emission computed tomography.
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decided that patients should not receive their intended
treatment did not know whether the PET or SPECT
results were used for determination of patient management.
The time from randomization to the second discussion by
the revascularization team was not different between the
13N-ammonia/18FDG PET and 99mTc-sestamibi SPECT
groups (35 6 3 vs. 40 6 3 days for PET and SPECT,
respectively), and neither was the time from the second
discussion to CABG or PTCA (80 6 19 vs. 92 6 19 days
for PET and SPECT, respectively).
Cardiac events during follow-up. One patient was lost
during follow-up. The mean follow-up time from random-
ization was not different for patients randomized to 13N-
ammonia/18FDG PET or 99mTc-sestamibi SPECT (26 6
1 vs. 29 6 1 months [median 28 vs. 29] for PET and
SPECT, respectively). Three periprocedural cardiac events
were observed: one patient experienced occlusion of the
coronary artery after PTCA and had subsequent myocardial
infarction; one patient died during CABG; and one patient
had a perioperative myocardial infarction. All first cardiac
events after randomization are shown in Table 2, and there
was no difference in the occurrence of the first cardiac event
between the 13N-ammonia/18FDG PET and 99mTc-
sestamibi SPECT groups, as illustrated by the Kaplan-
Meier plot in Figure 2. No difference could be demonstrated
in cardiac events between the 13N-ammonia/18FDG PET
and 99mTc-sestamibi SPECT groups for patients assigned
to be revascularized and those assigned to drug treatment
(Fig. 3 and 4). No difference was found between the
13N-ammonia/18FDG PET and 99mTc-sestamibi SPECT
groups for the patients with an ejection fraction #30% and
.30%. Furthermore, no significant differences were ob-
served for noncardiac death (due to rectum carcinoma,
cerebrovascular accident, diabetic coma or pulmonary em-
bolism; 3 vs. 1), hospital admission for heart failure (8 vs. 6)
or hospital admission for unstable angina (8 vs. 12) for the
PET and SPECT groups, respectively. Multivariate analysis
revealed no subgroups that might benefit from 13N-
ammonia/18FDG PET and 99mTc-sestamibi SPECT in
terms of cardiac event-free survival.
DISCUSSION
The present study is the first prospective, randomized study,
to our knowledge, addressing the impact of 13N-ammonia/
18FDG PET imaging, as compared with stress/rest 99mTc-
sestamibi SPECT imaging, on patient management and
long-term prognosis in patients who are candidates for
revascularization with suspicion of jeopardized myocardium.
We demonstrated that treatment based on assessment of
jeopardized myocardium with 13N-ammonia/18FDG PET
did not result in differences in patient management and,
more importantly, in cardiac event-free survival, as com-
pared with treatment based on 99mTc-sestamibi SPECT
imaging. Furthermore, for both 13N-ammonia/18FDG
Figure 3. Kaplan-Meier cardiac event-free survival curves for patients in-
tended to undergo revascularization on the basis of 13N-ammonia/18FDG
PET or stress/rest 99mTc-sestamibi SPECT imaging. CABG 5 coronary
artery bypass graft surgery; 18FDG 5 18fluorodeoxyglucose; PET 5 positron
emission tomography; PTCA 5 percutaneous transluminal angioplasty;
SPECT 5 single-photon emission computed tomography.
Table 2. First Cardiac Event per Patient After Randomization
Events
PET Group (n 5 49) SPECT Group (n 5 54)
PET
Total
SPECT
Total
p
Value
PTCA
(n 5 12)
CABG
(n 5 14)
Intended
Drugs
(n 5 23)
Treatment
PTCA
(n 5 15)
CABG
(n 5 13)
Drugs
(n 5 26)
PTCA 0 1 0 2 0 2 1 4 NS
CABG 1 1 2 2 2 1 4 5 NS
MI 0 0 2 0 1 2 2 3 NS
Cardiac death 2 1 1 0 1 0 4 1 NS
Data are presented as number of patients.
Abbreviations as in Table 1.
Figure 2. Kaplan-Meier cardiac event-free survival curves for patients
randomized to 13N-ammonia/18FDG PET or stress/rest 99mTc-sestamibi
SPECT-based management (PTCA, CABG or drug therapy). All patients
were potential candidates for revascularization, and in all patients, assess-
ment of jeopardized myocardium was indicated. CABG 5 coronary artery
bypass graft surgery; 18FDG 5 18fluorodeoxyglucose; PET 5 positron
emission tomography; PTCA 5 percutaneous transluminal angioplasty;
SPECT 5 single-photon emission computed tomography.
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PET-guided management and 99mTc-sestamibi SPECT
imaging-guided management, the number of cardiac events
was comparable for patients assigned to revascularization
and those assigned to drug therapy. No specific subgroups
benefiting from either 13N-ammonia/18FDG PET-guided
management or 99mTc-sestamibi SPECT-guided manage-
ment could be identified in terms of cardiac event-free
survival.
Nitrogen-13–ammonia/18FDG PET and 99mTc-
sestamibi SPECT. In clinical practice, identification of
patients who may benefit from revascularization is an
important issue. To date, only nonrandomized and mostly
retrospective studies have been performed to evaluate pa-
tient management and prognosis based on viability assess-
ment (12–16), but in none of these studies was the revas-
cularization team blinded to the nuclear technique on which
patient management was determined. Consequently, a bias
for referral to revascularization or drug treatment could have
existed. Nevertheless, these studies suggest that when jeop-
ardized myocardium is present, revascularization may result
in a better prognosis than drug treatment. Therefore,
treatment based on the presence or absence of jeopardized
myocardium appears critically important, and in our opin-
ion, this should be the cornerstone of revascularization
management in clinical practice.
Both 13N-ammonia/18FDG PET imaging and 99mTc-
sestamibi SPECT imaging are able to identify patients with
jeopardized myocardium who may benefit from revascular-
ization in terms of clinical outcome (12–15) and postrevas-
cularization recovery of left ventricular function (3,5–21).
However, 99mTc-sestamibi SPECT imaging is thought to
be less accurate for detection of viability, as preserved
18FDG uptake was demonstrated in 99mTc-sestamibi de-
fects (35–37). Whether 13N-ammonia/18FDG PET and
99mTc-sestamibi SPECT imaging have a different impact
on prognosis and patient management is unknown. The
present study addresses this specific issue and demonstrates
that in clinical patient management, the use of the specific
viability tracer 18FDG combined with 13N-ammonia in
PET imaging did not result in different management and
different long-term cardiac event-free survival, as compared
with stress/rest 99mTc-sestamibi SPECT imaging. Al-
though this study was not intended to compare PET and
SPECT in a head-to-head fashion, when comparing the
amount of normal, jeopardized and nonviable myocardium
in all 103 PET and 103 SPECT uniform polar maps, no
difference between the PET and SPECT groups was
observed. We presume that this lack of difference is an
important reason for not observing a difference in manage-
ment and, more importantly, in cardiac event-free survival
between the PET- and SPECT-based management groups.
To detect jeopardized myocardium, established criteria
were used. For 99mTc-sestamibi, we used a 50% cutoff value
of maximal activity criteria to optimize detection of jeopar-
dized myocardium (36,38), and for 13N-ammonia/18FDG
PET imaging, we used mismatch and match criteria, as
previously described by Blanksma et al. (33). If 99mTc-
sestamibi SPECT in our study had substantially underesti-
mated viability, as compared with 18FDG PET, then
patients randomized to 99mTc-sestamibi SPECT–based
management were expected to be treated with drugs more
frequently and to show high event rates, as reported in
drug-treated patients exhibiting jeopardized myocardium
(12–14,39). Moreover, the event rates in the drug-treated
patients randomized to 99mTc-sestamibi SPECT would
have been higher than those in the drug-treated patients
randomized to 13N-ammonia/18FDG PET. In our study,
this was not observed. In fact, the drug-treated patients in
both the 13N-ammonia/18FDG PET and 99mTc-sestamibi
SPECT groups demonstrated event rates consistent with an
absence of residual jeopardized myocardium, as reported in
prognostic 18FDG studies (12–14,16,20). Ideally, only pa-
tients exhibiting jeopardized myocardium would be revas-
cularized, accompanied by a relatively low event rate at
long-term follow-up. The revascularized patients random-
ized to 13N-ammonia/18FDG PET showed relatively low
event rates, in agreement with published data (12–
14,16,20), and the event rates of revascularized patients
randomized to 99mTc-sestamibi SPECT were not different.
Thus, the prognostic value for event rates of 13N-ammonia/
18FDG PET–based management is consistent with previ-
ous data, and the 99mTc-sestamibi SPECT event rates are
not different.
In our study, we did not discriminate between ischemic
myocardium and nonischemic but viable myocardium. Both
PET and SPECT perfusion imaging were performed with
pharmacologic stress. For PET imaging, the combination of
stress perfusion with 18FDG permits the identification of
hibernating myocardium, as well as stress-induced ischemia
(21). For 99mTc-sestamibi SPECT, jeopardized myocar-
dium was identified by detecting both ischemic and nonisch-
emic but viable segments, by using reversibility criteria and
50% of maximal tracer uptake. As suggested by Bonow (40)
and applied in the present study, jeopardized myocardium
should be revascularized because both hibernating myocar-
dium and stress-induced ischemia may benefit from it.
Figure 4. Kaplan-Meier cardiac event-free survival curves for patients
intended to be treated with drugs on the basis of 13N-ammonia/18FDG
PET or stress/rest 99mTc-sestamibi SPECT imaging.
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Study limitations. This study was designed to provide
more insight on clinical relevance of assessment of jeopar-
dized myocardium in terms of prognosis, as suggested by
Bonow (40). Therefore, no data on functional status of
patients were obtained during follow-up, and the interesting
relation between functional outcome and prognosis remains
unexplored in the present study. Patency after revascular-
ization was only assessed when indicated clinically, because
this study was designed to evaluate patient management in
a practical clinical setting. Although all patients in our study
had wall motion abnormalities, ;35% of all them had left
ventricular ejection fraction ,30%. Because this is a rela-
tively small number, the applicability of the present results
for this specific group needs further study. Eight patients
did not receive the intended treatment, two of whom died
before they were revascularized. The remaining six patients
experienced no cardiac events during follow-up; however, it
appears that more patients in the SPECT group (n 5 5) did
not receive the intended treatment, as compared with those
in the PET group (n 5 1). In three patients, the decision to
treat differently than intended had no relation to the
randomized technique. For the remaining three treatment
changes, we could not identify whether they were due to
either false positive or false negative imaging results, because
this study provided no gold standard. Nevertheless, these
changes from intended treatment illustrate that the clinical
condition of the patients remains important to treating
physicians in clinical practice.
Study implications and conclusions. Patient management
based on identification of jeopardized (i.e., ischemic or
viable) myocardium with 13N-ammonia/18FDG PET and
stress/rest 99mTc-sestamibi SPECT imaging does not result
in different cardiac event-free survival and different patient
management in patients who are candidates for revascular-
ization with suspicion of jeopardized myocardium. Our
results demonstrate that both 13N-ammonia/18FDG PET
and 99mTc-sestamibi SPECT imaging accurately identified
patients who should be revascularized or treated with drugs,
based on the presence or absence of jeopardized myocar-
dium. Therefore, both 13N-ammonia/18FDG PET and
99mTc-sestamibi SPECT imaging may be used for deter-
mination of patient management in a clinical setting.
The previously reported (28) differences in sensitivity and
specificity between 13N-ammonia/18FDG PET and 99mTc-
sestamibi SPECT for recovery of left ventricular function
were not reflected in a different prognosis, neither in the
total study group nor in the specific subgroups. Further
studies are needed to evaluate the accuracy of other viability
detection techniques in patient management in terms of
prognosis. Moreover, the relation between left ventricular
functional recovery and prognosis should be explored, as
recovery of function might not be the sole factor influencing
prognosis (41).
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